Augmented renal clearance (ARC) refers to the enhanced renal excretion of circulating solute commonly demonstrated in numerous critically ill subgroups. This study aimed to describe the prevalence of ARC in critically ill Indigenous Australian patients and explore the accuracy of commonly employed mathematical estimates of glomerular filtration. We completed a single-centre, prospective, observational study in the intensive care unit (ICU), Alice Springs Hospital, Central Australia. Participants were critically ill adult Indigenous and non-Indigenous Australian patients with a urinary catheter in situ. Exclusion criteria were anuria, pregnancy or the requirement for renal replacement therapy. Daily eight-hour measured creatinine clearances (CrCL m ) were collected throughout the ICU stay. ARC was defined by a CrCL m ≥130 ml/min/1.73 m 2 . The CockcroftGault and Chronic Kidney Disease Epidemiology Collaboration equations were also used to calculate mathematical estimates for comparison. In total, 131 patients were recruited (97 Indigenous, 34 non-Indigenous) and 445 samples were collected. The median (range) CrCL m was 93.0 (5.14 to 205.2) and 90.4 (18.7 to 206.8) ml/min/1.73 m 2 in Indigenous and non-Indigenous patients, respectively. Thirty-one of 97 (32%) Indigenous patients manifested ARC, compared to 7 of 34 (21%) non-Indigenous patients (P=0.21). Younger age, major surgery, higher baseline renal function and an absence of diabetes were all associated with ARC. Both mathematical estimates manifest limited accuracy. ARC was prevalent in critically ill Indigenous patients, which places them at significant risk of underdosing with renally excreted drugs. CrCL m should be obtained wherever possible to ensure accurate dosing.
, and can lead to detrimental clinical outcomes. An acute reduction in renal function, commonly referred to as acute kidney injury (AKI), is a form of end-organ dysfunction which is associated with a worse prognosis 3 . From a pharmacological perspective, it leads to accumulation of renally eliminated drugs and increased risk of toxicity. On the other hand, compelling data over the past decade describes a phenomenon in critical illness termed augmented renal clearance (ARC), which is characterised by an increase in renal solute excretion 1 . The prevalence of ARC is reported as between 30% and 65% in those with normal serum creatinine concentrations (SCr) 4 . ARC is of particular interest, as it is associated with low serum concentrations for renally eliminated drugs [5] [6] [7] [8] . Commonly used antibiotics in the intensive care unit (ICU) such as beta-lactams and glycopeptides are susceptible to such an effect, resulting in subtherapeutic drug concentrations 7, 9, 10 and potentially worse clinical outcomes 11 . Critically ill Indigenous Australian patients have high morbidity and mortality rates 12 . They are generally younger and have greater sickness severity 12, 13 . However, the prevalence of ARC has not been described in this population, although Indigenous Australians are reported to have 30% fewer nephrons as compared with their non-Indigenous counterparts 14 . This is theorised to be a leading cause of the high prevalence of chronic kidney disease (CKD) in this population, and may impact the development of ARC.
In addition, numerous methods to determine the glomerular filtration rate (GFR) are available. Over the last decade, various mathematical equations to estimate GFR (eGFR) have been widely implemented, despite concerns about their application in specific populations 15, 16 . Indeed, a recent study has suggested the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation has the greatest accuracy in non-critically ill Indigenous Australian patients 17 , although no data are available for this group in the ICU.
Therefore the aims of this study were to 1) describe the prevalence of ARC in critically ill Indigenous Australian patients, 2) identify clinical characteristics associated with ARC in this group, and 3) study the degree of agreement between various existing eGFR equations, and measured urinary creatinine clearance (CrCL m ).
Materials and methods
This was a prospective, observational cohort study of critically ill Indigenous Australian and non-Indigenous patients admitted to a general ten-bed ICU in Alice Springs Hospital, Northern Territory. This ICU has approximately 700 admissions per annum, 60% of whom are Indigenous Australians. Patients requiring specialised surgical and medical services are transferred to tertiary hospitals, the nearest being 1,500 km away. Ethical approval was granted by the local (Central Australian Human Research Ethics Committee, approval code HREC-15-309) and university (the University of Queensland Human Research Ethics Committee, approval code 2015000820) ethics committees, and a waiver of consent was granted.
Study population
The inclusion criteria were: 1) ≥18 years of age; 2) admitted to ICU; 3) an indwelling urinary catheter in situ; and 4) expected ICU stay for ≥24 hours. The exclusion criteria were 1) anuria; 2) requiring haemodialysis or continuous renal replacement therapy; 3) pregnancy; or 4) treating clinician considered the patient unsuitable for enrolment.
Patients were initially identified as Indigenous Australians or non-Indigenous Australians on the basis of recorded ethnicity in the hospital's administration system, which assigns patient ethnicity mainly by self-identification and family groupings. Individuals of mixed heritage are recorded as Indigenous in the hospital system, and a small number were included in the study in the Indigenous Australian group.
Study protocol
All patients were screened upon ICU admission on all days of the week. In those meeting the inclusion criteria, and none of the exclusion criteria, the total amount of urine excreted between 0300 and 1100 hours every day was collected in a two litre urine container via the urinary catheter and sent to the local hospital pathology laboratory. The volume of urine and exact duration of urine collection were recorded. The creatinine concentration in the urine sample was assayed using the VITROS® CREA (Ortho-Clinical Diagnostics Inc., Rochester, NY, USA) slide method with the Vitros fusion 5.1 analyser.
Demographic and clinical data collected included age, ethnicity, gender, height, weight, diabetes status, baseline serum creatinine concentration (SCr), baseline glomerular filtration rate according to the CKD-EPI equation (eGFR CKD-EPI ), inotrope usage, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, length of ICU and hospital stay and admission diagnosis.
Methods to quantify GFR
Creatinine clearance was both measured (CrCL m ) and calculated using the Cockcroft-Gault equation (CrCL CG ). eGFR was also calculated using the CKD-EPI equation. Table 1 describes each method in detail. The SCr used in these calculations was extracted from the routine laboratory test performed between 0500 and 0600 hours on each sampling day and was determined using the VITROS CREA slide method. All values were normalised to a body surface area of 1.73 m 2 .
Data analysis
ARC was defined as a CrCL m ≥130 ml/min/1.73 m 2 as it is correlated with subtherapeutic antibiotic concentrations when conventional doses are used 1, 8 . Different levels of renal dysfunction were categorised in accordance with the RIFLE (Risk, Injury, Failure, Loss, End-stage renal disease) criteria 18 . Risk of AKI (rAKI) was defined as a 1.5 to <2 times increase from baseline SCr; AKI was defined as 2 to <3 times increase from baseline SCr; and acute renal failure (ARF) was defined as ≥3 times increase from baseline SCr or SCr >354 µmol/l with an acute rise of >44 µmol/l. The baseline SCr was obtained from previous admissions, clinic letters or medical records. Where a baseline SCr was not available, this was 'back-calculated' using the CKD-EPI equation.
The prevalence of ARC, rAKI, AKI and ARF were compared between Indigenous and non-Indigenous patients. This was calculated as the number of patients who met these criteria on at least one occasion during their ICU stay, over the total number of patients in each group. Diabetes status was obtained from the patient's medical record. Demographic and clinical data associated with ARC in Indigenous patients were also assessed.
Statistical analysis
Data were analysed using SPSS 23.0 for Windows (SPSS, Chicago, IL, USA). Continuous data are presented as the median (interquartile range) or mean (standard deviation), and categorical data presented as counts (%), as appropriate. Between-patient differences were assessed using a Student's t-test, Mann-Whitney U-test, or chi-squared test. BlandAltman plots were used to assess the precision and bias of different mathematical equations using CrCL m as the reference. These mathematical equations include eGFR CKD-EPI and CrCL CG calculated using total body weight (TBW) and lean body weight using the James, Boer and Hume formulae (LBW J , LBW B and LBW H , respectively) [19] [20] [21] . A P-value of <0.05 was considered as statistically significant.
Results
Study recruitment was conducted over the five-month period from 1 June to 31 October 2015. The process for patient enrolment is presented in Figure 1 . A total of 131 patients (97 Indigenous and 34 non-Indigenous) were included, providing 445 urine samples. Demographic and clinical data are presented in Table 2 . Indigenous and nonIndigenous patients provided a similar number of urinary collections (median of 2 (1 to 4) per Indigenous patient, and 2 (1 to 5) per non-Indigenous patient). The Indigenous patient group had more females, was significantly younger and had a higher prevalence of sepsis and diabetes.
Prevalence of ARC, rAKI, AKI, and ARF
The prevalence of ARC, rAKI, AKI and ARF are presented in Table 3 . There were no statistically significant differences between the two study groups in terms of this measure.
Determinants of ARC in Indigenous patients and assessment of accuracy of mathematical equations
A comparison of demographic and clinical characteristics between Indigenous patients with and without ARC is presented in Table 4 . Indigenous patients who developed ARC were significantly younger, had a higher baseline eGFR CKD-EPI (and lower baseline SCr), were more likely to have had major surgery and less likely to have diabetes. Figure 2 and Table 5 . All tested equations show limited agreement with CrCL m . Overall, CrCL CG calculated with TBW showed the lowest bias and highest precision. However, eGFR CKD-EPI has the narrowest 95% confidence interval for limits of agreement in the Bland-Altman analysis.
Discussion

Key findings
To our knowledge, this is the first study to describe CrCL m in critically ill Indigenous Australian patients. We observed a prevalence of ARC of 32% (31 of 97 patients) in this group. Furthermore, we identified significant associations between ARC and younger age, major surgery, the absence of diabetes, and a baseline eGFR CKD-EPI >90 ml/min/1.73 m 
Relationship with previous studies
The prevalence of ARC detected in the Indigenous group is consistent with that reported in other critically ill populations (30%-65%), albeit at the lower end of the range 1 . A potential explanation is that patients with CKD or high SCr were excluded in most other studies exploring the epidemiology of ARC. Approximately 2% of the Indigenous Australian population self-report to have CKD, which is ten times more than non-Indigenous Australians 22 . The unusually high prevalence of CKD in this unique population may further contribute to the relatively low prevalence of ARC reported in our data.
Numerous risk factors for ARC have been identified, including: male gender, younger age, multiple trauma, mechanical ventilation, sepsis, and use of inotropes 9, 11 . In our study, we found ARC was most likely in Indigenous patients who were younger, did not have diabetes, had high baseline eGFR and had undergone major surgery. The exceptionally high prevalence of diabetes in the Indigenous Australian population is likely to explain its inverse association with ARC, as poorly controlled diabetes is commonly associated with CKD. Of note, critically ill Indigenous patients in the Australian ICU setting are 10 to 15 years younger compared with nonIndigenous comparators 12 , and this was a consistent finding in our study. Indeed, the higher numerical prevalence of ARC observed in the Indigenous group (as opposed to nonIndigenous patients), is likely to reflect the younger age of these patients.
The limited accuracy of the eGFR equations in comparison to CrCL m is in agreement with previously published data 23 . The mathematical equations are heavily dependent on SCr, which does not immediately reflect the transient fluctuations of renal function observed in critical illness. The precision and bias are similar between most equations, although CrCL CG marginally manifests the lowest bias and highest precision. However, a recent study suggested eGFR CKD-EPI as the most accurate formula for optimising vancomycin therapy in critically ill patients, as compared with CrCL CG and modification of diet in renal disease (MDRD) eGFR 24 . Of note, eGFR CKD-EPI is likely to underestimate the GFR in critically ill patients and its accuracy worsens significantly with higher creatinine clearances 4, 24, 25 . The combined prevalence of AKI/ARF for the Indigenous group was 21%, compared to 11% in the non-Indigenous group. These are higher than have been reported previously in the ICU 26 (ARF criteria in this study were the use of renal replacement therapy, oliguria or marked azotaemia), and in the case of Indigenous Australians, may be due to the higher prevalence of CKD.
Study implications
ARC was identified in approximately one in three Indigenous patients, reminding the clinician that any wholesale assumptions about renal function in this group are likely to be flawed. As such, obtaining routine CrCL m Table 4 Comparison of Indigenous patients with and without augmented renal clearance Such findings require greater attention in clinical practice as the presence of ARC has been correlated with subtherapeutic concentrations of drugs that are predominantly renally eliminated, which encompasses most commonly used antibiotics in the ICU 6, 7 . ARC has also been reported in studies describing the pharmacokinetics of commonly used antibiotics in critically ill Indigenous Australian patients with severe sepsis, where higher doses and/or dosing frequencies are recommended 27, 28 . Such dose optimisation should be considered imperative, as the presence of ARC in critically ill patients requiring antibiotics has been correlated with worse clinical outcomes 11 . Nonetheless, a consensus has yet to be reached regarding the best approach to antibiotic dosing in the presence of ARC.
Strengths and limitations
There are some limitations to this study. CrCL m includes creatinine excreted by tubular secretion, creating a source of error when compared with actual GFR, especially for patients with low CrCL m 4 . While it would have been ideal to use an exogenous filtration marker (such as inulin or radionucleotide analogues), the application of such techniques is not practical in the ICU. Furthermore, CrCL m is widely recommended for use in critical illness 15, 29 , and is often considered a surrogate of GFR in routine clinical practice.
Our study is significantly limited by its small sample size, such that we were unable to undertake further sensitivity or longitudinal analysis. In this case, our results should be viewed with caution, and require validation in a larger, multicentre cohort. Having said this, our study still provides useful observational data concerning renal function in critically ill Indigenous patients, representing an at-risk group for which there is a paucity of contemporary literature. In particular, our study provides unique data comparing the accuracy of varying methods to estimate GFR in this setting. Finally, as this is not a pharmacokinetic/pharmacodynamic study, alterations of pharmacokinetics or clinical outcomes due to the presence of ARC for patients requiring pharmacotherapy cannot be assessed. Importantly however, a large number of studies have previously established the association between ARC and suboptimal drug exposure [5] [6] [7] [8] [9] [10] .
Future studies
A large prospective multicentre study is needed to clarify the relationship between the manifestation of ARC and clinical outcomes in critically ill Indigenous Australian patients requiring antibiotic therapy. Furthermore, pharmacokinetic studies are also needed to describe optimal antibiotic doses for different levels of ARC.
Conclusion
ARC is prevalent in critically ill Indigenous Australian patients, leading to a significant risk of underdosing with renally excreted drugs. Risk factors of ARC in critically ill Indigenous patients include younger age, the absence of CKD, the absence of diabetes and recent major surgery. All mathematical equations tested demonstrated limited accuracy in comparison with CrCL m , and hence urinary CrCL m should be obtained whenever ARC is suspected.
